FDA Releases Final Guidance On External Clinical Study Monitors
This article was originally published in The Gray Sheet
Executive SummaryFinal guidance issued by FDA March 28 acknowledges device company concerns about the burden of clinical trial data monitoring committees, but stops short of acquiescing to requests to substantially change its 2001 draft recommendations
You may also be interested in...
Updated data from a postmarket study of Abiomed’s Impella RP right-heart pump further supports the device’s safety for a specific patient population.